Biomarkers for Epigenetic Therapy of Lung Cancer

Primary Objective To measure reversal of aberrant genome-wide promoter methylation and gene re-expression in paired, pre- and post- treatment lung tumor pairs from patients with newly diagnosed, surgically resectable non-small cell lung cancer before and after exposure to a single neoadjuvant cycle of 5-Azacytidine and entinostat. Secondary Objectives 1. To measure the 3-year disease-free survival of operable NSCLC patients who receive 1 cycle of preoperative epigenetic treatment. 2. To determine any potential toxicities, and reversibility of toxicities, of a single pre-operative cycle of 5-Azacytidine and entinostat.